24/03/2016
Fidia Farmaceutici has now a subsidiary in the Middle East
Fidia Farmaceutici has established a wholly owned subsidiary in Middle East, further enhancing its presence in growing markets.
Continuing its International growth, Fidia farmaceutici, a world leader in hyaluronic acid R&D and manufacturing, announces the opening of a wholly owned subsidiary in the United Arab Emirates. A hub for its operations in the Middle East and North Africa (MENA), Fidia’s 6th subsidiary will be based in Dubai.
The Dubai subsidiary will also provide field support to Fidia farmaceutici’s customers and distributors in the region more thoroughly and effectively, to ensure they receive the highest quality service.
Fidia Pharma Middle East was formally inaugurated on December 1st, 2015 and employs highly professional and dedicated people, with a diversified product portfolio focusing on hyaluronic acid, with specialization in intra-articular Joint Care, Wound Care and Aesthetic Medicine.
The completion of this project further demonstrates Fidia’s transition into a truly global business, and strategic investment into key emerging markets, such as the Middle East.
The Dubai subsidiary will also provide field support to Fidia farmaceutici’s customers and distributors in the region more thoroughly and effectively, to ensure they receive the highest quality service.
Fidia Pharma Middle East was formally inaugurated on December 1st, 2015 and employs highly professional and dedicated people, with a diversified product portfolio focusing on hyaluronic acid, with specialization in intra-articular Joint Care, Wound Care and Aesthetic Medicine.
The completion of this project further demonstrates Fidia’s transition into a truly global business, and strategic investment into key emerging markets, such as the Middle East.
